Arvinas to Participate in Upcoming Investor Conferences
Arvinas (Nasdaq: ARVN), a clinical-stage biotech company focusing on targeted protein degradation, announced participation in two prominent investor conferences. On June 6, 2024, John Houston, Ph.D., CEO and President, and Noah Berkowitz, M.D., Ph.D., CMO, will join a fireside chat at the Jefferies Global Healthcare Conference in NYC.
The team will also attend the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, in Miami, featuring another fireside chat. Both events will be webcast live, accessible through Arvinas' website's Events + Presentations section.
- Participation in major investor conferences highlights Arvinas' proactive engagement with the investment community.
- Webcasts of presentations increase accessibility and transparency for shareholders and potential investors.
- CEO and CMO involvement underscores the company's commitment to communicating strategic and clinical milestones.
- The announcement lacks specific updates on financial performance or clinical progress, which may disappoint some investors seeking detailed information.
- No new data or partnerships announced, potentially limiting immediate positive impact on stock price.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:
- Jefferies Global Healthcare Conference on Thursday, June 6 in New York City.
- John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
- Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10 in Miami.
- John Houston, Ph.D., Chairperson, Chief Executive Officer and President, and Noah Berkowitz, M.D., Ph.D., Chief Medical Officer, will participate in a fireside chat. A live audio webcast of the presentation will be available here and on the Events + Presentations section of the Company’s website.
About Arvinas
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and “undruggable” targets, the company has three investigational clinical-stage programs currently enrolling: vepdegestrant for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102 for the treatment of patients with neurodegenerative disorders, and ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas.
In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. For more information, visit www.arvinas.com.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kathleen Murphy
+1 (760) 622-3771
Kathleen.Murphy@arvinas.com
FAQ
What events is Arvinas (ARVN) participating in?
When will Arvinas (ARVN) present at the Jefferies Global Healthcare Conference?
Who will represent Arvinas (ARVN) at the investor conferences?
Will the Arvinas (ARVN) presentations be available online?
